跳至主要内容
临床试验/NCT04089423
NCT04089423已完成不适用

Prospective Multicentre Evaluation of the Accuracy and Diagnostic Yield of the Fujifilm SILVAMP TB LAM (FujiLAM) Test for the Diagnosis of Tuberculosis in People Living With HIV

Foundation for Innovative New Diagnostics, Switzerland7 个研究点 分布在 7 个国家目标入组 1,731 人开始时间: 2019年12月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,731
试验地点
7
主要终点
Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined CRS.

研究概览

简要总结

This is a prospective, multicentre cohort study in which the accuracy and the diagnostic yield of the FujiLAM test will be assessed using a microbiological reference standard, an extended microbiological reference standard and a composite reference standard among inpatient and outpatient people living with HIV (PLHIV).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult PLHIV (≥18 years), irrespective of their CD4 count and antiretroviral therapy (ART) status, at risk of having pulmonary and/or extra-pulmonary TB
  • Inpatients: irrespective of TB symptoms
  • Outpatients: at least one of the symptoms suggestive of TB (as defined by WHO*)
  • written informed consent
  • willingness to have a trial follow-up visit at 2-3 and 6 months after enrolment (e.g. not planning to relocate)

排除标准

  • Current anti-TB treatment *
  • Any anti-TB treatment within 60 days prior to enrolment
  • Any isoniazid preventive therapy within 6 months prior to enrolment * Patients starting anti-TB treatment at the time of enrolment will not be excluded from the trial provided that all trial specimens are collected before starting the 3rd dose of treatment.

结局指标

主要结局

Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined CRS.

时间窗: Day 1

Point estimates of sensitivity and specificity of FujiLAM, with 95% confidence intervals, using the defined eMRS.

时间窗: Day 1

Diagnostic yield, with 95% confidence interval, of FujiLAM test among eMRS positive patients and AlereLAM, Smear and Ultra (sputum, urine) as comparators (on Day 1 specimens).

时间窗: Day 1

次要结局

未报告次要终点

研究者

发起方
Foundation for Innovative New Diagnostics, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验